Top Markets
Coin of the day
Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087
Clasificación en acciones #3185
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Precio por acción
$10.35
Capitalización bursátil
$6.19B
Cambio (1 día)
3.79%
Cambio (1 año)
4.34%
País
CN
Comercio Gan & Lee Pharmaceuticals. (603087)

Categoría

Ganancias de Gan & Lee Pharmaceuticals. (603087)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Gan & Lee Pharmaceuticals., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Gan & Lee Pharmaceuticals. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$3.81B -
US
$4.11B -
FR
- -
JP
$1.59B -
US
- -
CH